BOCH
VKTX icon

Blue Owl Capital Holdings’s Viking Therapeutics VKTX Stock Holding History

Blue Owl Capital Holdings’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-95,000
Closed -$5.57M – 138
2024
Q2 		$5.04M Buy
+95,000
New +$6.23M 1.4% 20

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Blue Owl Capital Holdings's VKTX Position: Q3 2024 in Review

Blue Owl Capital Holdings sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 95,000 shares — an estimated $5.57M sold.

Blue Owl Capital Holdings first reported a position in VKTX in Q2 2024 and held it in 1 quarter. The position peaked at $5.04M in Q2 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Blue Owl Capital Holdings reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Blue Owl Capital Holdings sold 95,000 Viking Therapeutics shares in Q3 2024, an estimated $5.57M.
  • Blue Owl Capital Holdings first reported a position in Viking Therapeutics in Q2 2024 and held it in 1 quarter.
  • Blue Owl Capital Holdings's Viking Therapeutics position peaked at $5.04M in Q2 2024.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Blue Owl Capital Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.